|
Volumn 133, Issue 6, 2000, Pages 471-473
|
Assessing the benefits of antiretroviral therapy
|
Author keywords
[No Author keywords available]
|
Indexed keywords
ANTIRETROVIRUS AGENT;
CD4 ANTIGEN;
PROTEINASE INHIBITOR;
CELL COUNT;
CLINICAL TRIAL;
DRUG EFFECT;
DRUG EFFICACY;
DRUG MECHANISM;
DRUG POTENCY;
EDITORIAL;
HUMAN;
HUMAN IMMUNODEFICIENCY VIRUS INFECTION;
IMMUNE DEFICIENCY;
MEDICAL DECISION MAKING;
PRIORITY JOURNAL;
PROGNOSIS;
PROTEINASE INHIBITION;
SURVIVAL RATE;
TREATMENT OUTCOME;
VIRUS GENE;
VIRUS LOAD;
VIRUS REPLICATION;
|
EID: 0034687061
PISSN: 00034819
EISSN: None
Source Type: Journal
DOI: 10.7326/0003-4819-133-6-200009190-00016 Document Type: Editorial |
Times cited : (11)
|
References (20)
|